• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Greenwich LifeSciences, Inc. - Common stock (NQ:GLSI)

    16.82 -0.31 (-1.81%)
    Delayed Quote Updated: 1:23 PM EDT, Oct 27, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Greenwich LifeSciences, Inc. - Common stock

    < Previous 1 2 3 4 Next >
    InvestorNewsBreaks – Greenwich LifeSciences, Inc. (NASDAQ: GLSI) Highlights Phase 3 Trial Progress and Expanded Study Design
    Via Investor Brand Network
    News headline image
    Why Is GLSI Stock Rising Today? ↗
    Greenwich LifeSciences said its Phase III breast cancer immunotherapy trial, involving 250 patients, showed a recurrence rate of under 1% per year. 
    Via Stocktwits
    Topics Economy Government
    News headline image
    Greenwich LifeSciences Stock Jumps After FDA Update ↗
    Greenwich LifeSciences, Inc. (NASDAQ:GLSI) shares are trading higher after the company announced the Food and Drug Administration approved the use of its first commercially manufactured GP2 lot for the... 
    Via Benzinga
    Stay updated with the stocks that are on the move in today's pre-market session. ↗
    Via Chartmill
    News headline image
    Insiders Buying Greenwich LifeSciences And 2 Other Stocks ↗
    Although U.S. stocks closed mostly lower on Friday, there were a few notable insider trades. 
    Via Benzinga
    Greenwich LifeSciences Inc. (NASDAQ: GLSI) Near the Top of Equities by Percentage Gain on 2/14
    Via Investor Brand Network
    News headline image
    Why Did Greenwich LifeSciences Stock Soar Pre-Market Today? ↗
    The company disclosed that the Food and Drug Administration (FDA) has reviewed and authorized the use of its first commercially produced batch of the GP2 drug product in the ongoing FLAMINGO-01 trial. 
    Via Stocktwits
    News headline image
    Keep an eye on the top gainers and losers in Monday's session. ↗
    Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
    Via Chartmill
    News headline image
    Why Did GLSI Stock Surge 25% Today? ↗
    The company’s Board extended the lock-up on shares held by directors, officers, and pre-IPO investors through Sept. 30, 2026. 
    Via Stocktwits
    News headline image
    On Thursday, there are stocks with unusual volume. Let's take a look. ↗
    Let's have a look at the stocks with an unusual volume in today's session. 
    Via Chartmill
    News headline image
    Why Is GLSI Stock Rising Today? ↗
    Greenwich LifeSciences shares surged following the company’s announcement of positive results from its phase III clinical trial, FLAMINGO-01. 
    Via Stocktwits
    News headline image
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    Greenwich LifeSciences Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
    Via ACCESS Newswire
    News headline image
    12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    Glancy Prongay & Murray LLP Announces Investigation of Greenwich LifeSciences, Inc. (GLSI)
    From Glancy Prongay & Murray LLP
    Via Business Wire
    News headline image
    GLSI Stock Earnings: Greenwich LifeSciences Reported Results for Q2 2024 ↗
    Greenwich LifeSciences just reported results for the second quarter of 2024. 
    Via InvestorPlace
    News headline image
    Over $1M Bet On United Security Bancshares? Check Out These 3 Stocks Insiders Are Buying ↗
     
    Via Benzinga
    News headline image
    GLSI Stock Earnings: Greenwich LifeSciences Beats EPS for Q1 2024 ↗
    GLSI stock results show that Greenwich LifeSciences beat analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    News headline image
    12 Health Care Stocks Moving In Monday's After-Market Session ↗
     
    Via Benzinga
    News headline image
    GLSI Stock Earnings: Greenwich LifeSciences Misses EPS for Q4 2023 ↗
    GLSI stock results show that Greenwich LifeSciences missed analyst estimates for earnings per share the fourth quarter of 2023. 
    Via InvestorPlace
    News headline image
    HC Wainwright & Co. Maintains Buy Rating for Greenwich LifeSciences: Here's What You Need To Know ↗
     
    Via Benzinga
    News headline image
    Why Greenwich Lifesciences (GLSI) Stock Is Skyrocketing ↗
    Greenwich Lifesciences shares are trading higher by 30.6% Wednesday afternoon. The company provided an update on the Phase III clinical trial, Flamingo-01. 
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
     
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Friday's After-Market Session ↗
     
    Via Benzinga
    News headline image
    $4.7 Million Bet On Tilly's? Check Out These 3 Stocks Insiders Are Buying ↗
    Although US stocks closed higher on Tuesday, there were a few notable insider trades. 
    Via Benzinga
    News headline image
    Greenwich LifeSciences Provides Year End Update
    From Greenwich LifeSciences, Inc.
    Via Business Wire
    News headline image
    Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2023
    From Greenwich LifeSciences, Inc.
    Via Business Wire
    News headline image
    Why Coupa Software Shares Jumped Around 29%; Here Are 72 Biggest Movers From Wednesday ↗
    Gainers Kalera Public Limited Company (NASDAQ: KAL) jumped 76.9% to close at $0.1610 on Wednesday after gaining 9% on Tuesday. Kalera recently posted a Q3 loss of $0.05 per share. 
    Via Benzinga
    News headline image
    Bitcoin Holder MicroStrategy And 4 More Short Squeeze Stocks That Could Soar This Week ↗
    Potential short squeeze plays gained steam in 2021 and has continued through 2022 with new traders looking for the next huge move. 
    Via Benzinga
    < Previous 1 2 3 4 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.